Treatment of maternal chronic myeloid leukemia with imatinib mesylate is avoided because of potential fetal effects. Two women with progression of disease during pregnancy required imatinib therapy. Concentrations of imatinib in maternal blood, placenta, umbilical cord blood and breast milk were 886, 2452, 0 to 157, and 596 ng/ml, respectively. Concentrations of the active metabolite CGP74588 in maternal blood, placenta, umbilical cord blood and breast milk were 338, 1462, 0 and 1513 ng/ml, respectively. As Imatinib and CGP74588 cross the mature placenta poorly, use of the drug after the first trimester may be reasonable under some circumstances. Imatinib and CGP74588 are found in breast milk, and therefore avoidance of breastfeeding is advisable.
Introduction
Chronic myeloid leukemia (CML) occurs in approximately one in 750 000 pregnancies. 1 CML cells often exhibit a chromosomal t(22:9) translocation, the Philadelphia chromosome (Ph). The protein product of this gene rearrangement, BCR-ABL, is a tyrosine kinase, which is leukemogenic. Imatinib mesylate, previously known as STI571, (Gleevec, Glivec, Novartis, Basel, Switzerland) inhibits the abnormal protein-tyrosine kinase. Because the side effect, safety and clinical response profiles of imatinib are excellent, it is a first-line agent for CML. 2 Most information regarding the reproductive effect of imatinib is derived from preclinical animal studies. In a rat model but not a rabbit model, high doses increased embryonic loss and malformations (exencephaly, encephalocele, and cranial bone hypoplasia). 3 Imatinib and its active metabolite, CGP74588, were detectable in the breast milk of rats.
There is little information regarding imatinib in human gestation. Accordingly, women are advised not to conceive while taking it. Yet, despite the counseling, at least 44 pregnancies have been reported. [4] [5] [6] [7] [8] [9] [10] A systematic search of Medline and Biosis databases from 1966 to 2006 using the terms imatinib mesylate, gleevec, glivec, STI571, pregnancy, gestation, placenta, umbilical cord blood and breast milk indicate that this is the first report of imatinib and CGP74588 concentrations in maternal blood, breast milk, umbilical cord blood and placenta.
Case 1
A multipara with a 3-year history of Ph-positive CML presented in the second trimester for prenatal care. Leukocytosis and splenomegaly developed in the third trimester. Hematology consultation was obtained, and because of progression of chronic-phase CML, imatinib 400 mg/day was started. There were no antenatal complications, and labor was induced at term resulting in an uneventful vaginal delivery of a healthy 3600 g female infant. Umbilical cord blood was collected at delivery, 38 h after a maternal dose of imatinib. Maternal blood was collected 11 h after an imatinib dose. Newborn examination, clinical course and hematologic indices were normal. Concentrations of imatinib and CGP74588 are shown in Table 1 .
Case 2
A multipara with a 1-year history of Ph-positive CML on maintenance imatinib therapy presented in the first trimester for prenatal care. Imatinib was discontinued after 4 weeks of pregnancy. In midgestation, she developed leukocytosis and thrombocytois. Hematology consultation recommended imatinib 400 mg/day for progression of chronic-phase CML. There were no antenatal complications and labor was induced at term resulting in an uneventful vaginal delivery of a 2995 g female infant. Umbilical cord blood was collected at delivery, 12 h after a maternal dose of imatinib. Newborn examination, clinical course, and hematologic indices were normal, with the exception of a 2 to 3 mm non-patent midline perineal pit. A placenta specimen was obtained and prepared by homogenization of cotyledon and vascular tissue. Breast milk was collected 7 days postpartum, 15 h after a dose of imatinib. Concentrations of imatinib and CGP74588 are shown in Table 1 .
Comment
Pregnancy in women with CML poses a management dilemma. Treatment is often deferred until disease progression, which is in contrast to the care of non-pregnant patients in whom chronic therapy with imatinib is recommended. 12 Unfortunately, 40% of women in hematologic remission on imatinib experience relapse during pregnancy with therapy interruption. 5 Despite its effectiveness and safety for the mother, when treatment is required, imatinib is usually not chosen because of limited data.
The pharmacological properties of imatinib are well characterized. The oral bioavailability is 98%, and the peak plasma concentration is achieved by 4 h. 13 The elimination half-lives of imatinib and CGP74588 are 13-22 and 40 h, respectively. Imatinib is 95% bound to plasma proteins, lipophilic, cytochrome P4503A metabolized, and has a molecular weight of 590.
14 On the 400 mg dose, the mean peak and trough plasma concentrations of imatinib are 2300 and 720 ng/ml, respectively. 15 Imatinib appears to cross the human placenta poorly. Because of contamination by maternal blood, the placental tissue concentration reflects the maternal serum concentration. The ratio of imatinib concentration in umbilical cord blood to placental was 0.064. This finding is not surprising as drugs that are highly bound to plasma proteins or have molecular weights higher than 500 have limited placental transfer. Additionally, drug-transporter proteins in the placenta may impede transfer. 16, 17 In contrast, high concentrations of imatinib and CGP74588 were detected in breast milk. However, a single measurement of a drug concentration in breast milk may not reflect a breast-fed infant's actual exposure as this varies with time. We estimate that if the time-averaged plasma milk ratio of imatinib and CGP74588 were in the range of our measurement, an infant consuming 600 to 1000 ml of milk would ingest between 1.2 to 2.0 mg of these materials daily (compared with the adult therapeutic imatinib dose of 400 mg/day). The risk to an infant consuming imatinib and metabolite at the levels observed in breast milk is unknown but is probably small. That being said, neither the long-term side effects of imatinib exposure nor the neonatal pharmacokinetics of imatinib metabolism are established. Imatinib inhibits the function of platelet derived growth factor receptor b (PDGFR b ), another tyrosine kinase receptor. Normal PDGFR b function is important for development of the peripheral microvascular system. PDGFR b is also involved in myelination of the peripheral nervous system. Theoretical effects of chronic imatinib exposure in the infant include abnormal growth of the peripheral microvasculature and peripheral nervous systems. 18, 19 Low imatinib and CGP74588 concentrations in umbilical cord blood suggest limited placental transfer in late pregnancy. Imatinib use may be reasonable under some circumstances during late gestation. However, given the limited experience in early gestation, advising women on imatinib to prevent pregnancy and exposure during organogenesis (postmenstrual days 31-71) remains prudent. Owing to the presence of imatinib and CGP74588 in the breast milk, avoidance of breastfeeding is advisable. As future cases of maternal disease requiring imatinib therapy arise, data should be collected to evaluate further the pharmacokinetics of imatinib during human gestation and lactation. All concentrations are in ng/ml. All specimens were stored at À701C until analyzed.
Concentrations were quantitated with a validated liquid chromatographic-mass spectrometric assay, using standard curves prepared in the appropriate control matrices.
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F, not determined.
